Abstract:OBJECTIVE:To investigate the prokaryotic expression of proteins pneumococcal endopeptidase O (PepO) and pneumococcal surface adhesin A (PsaA) in Streptococcus pneumoniae and their immunoprotective effect as vaccine candidate proteins.METHODS:Specific primers of target gene fragments were designed, and then PCR amplification was performed to establish recombinant plasmids pET28a(+)-pepO and pET28a(+)-psaA, which were transformed into host cells, Escherichia coli BL21 and DE3, respectively, to induce expression. Highly purified target proteins PepO and PsaA were obtained after purification. Mucosal immunization was performed for BALB/c mice and specific antiserum was prepared. ELISA was used to measure the antibody titer, and Western blot was used to analyze the specificity of the antiserum of target proteins. The mice were randomly divided into negative control group, PepO group, PsaA group, and PepO+PsaA combined immunization group, with 18 mice in each group. The models of different serotypes of Streptococcus pneumoniae infection were established to evaluate the immunoprotective effect of target proteins used alone or in combination.RESULTS:The target proteins PepO and PsaA were successfully obtained and Western blot demonstrated that the antiserum of these proteins had good specificity. There was no significant difference in the titers of IgA in saliva and IgG in serum between the PepO group and the combined immunization group (P>0.05); however, these two groups had significantly higher antibody titers than the PsaA group (P<0.05). The PepO, PsaA, and combined immunization groups had significantly higher protection rates for mice infected with Streptococcus pneumoniae D39 and CMCC31436 in the nasal cavity than the negative control group (P<0.05). The PepO and combined immunization groups had a significantly higher protection rate for mice infected with Streptococcus pneumoniae D39 than the PsaA group (P<0.05). The results of colonization experiment showed that compared with the control group, the PepO, PsaA, and combined immunization groups showed a significant reduction in the colonization of Streptococcus pneumoniae (CMCC31693 and CMCC31207) in the nasopharynx and lung (P<0.05). The combined immunization group showed a better effect on reducing the colonization of CMCC31207 in the lung than the PepO and PsaA alone groups.CONCLUSIONS:Combined PepO/PsaA vaccines may produce a better protective effect by mucosal immunization compared with the vaccine used alone in mice. The combined vaccines can effectively reduce the colonization of Streptococcus pneumoniae in the nasopharynx and lung. Therefore, such protein vaccines may have a great potential for research and development.

Mucosal Immune Effect of Group B Streptococcal Surface Immunogenic Protein

Immunogenicity and Function of Surface Immunogenic Protein of Group B Streptococcus

Intranasal Immunization with GBS Surface Protein Sip and ScpB Induces Specific Mucosal and Systemic Immune Responses in Mice

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines

Mucosal Vaccination with Lactococcus lactis-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model

System and intranasal immunization of group B streptococcal C5a peptide

Systemic and Mucosal Immune Responses in Mice after Mucosal Immunization with Group B Streptococcus Type III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccine

Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant

Evaluation of Immunization with the SIP Against Streptococcus Agalactiae-induced Mouse Mastitis

Mucosal Immunization Has Benefits over Traditional Subcutaneous Immunization with Group A Streptococcus Antigens in a Pilot Study in a Mouse Model

The Optimisation of the Expression of Recombinant Surface Immunogenic Protein of Group B Streptococcus in Escherichia coli by Response Surface Methodology Improves Humoral Immunity

The effect of immunization by recombinant Mycobacterium smegmatis encoding GLS and IL-12 in mice

[Study on the Bactericidal Antibody Against Neisseria Meningitidis Serogroup C Strains after Immunization with a Divalent Polysaccharide (A Plus C) Vaccine].

A CRISPRi Library Screen in Group B Streptococcus Identifies Surface Immunogenic Protein (Sip) as a Mediator of Multiple Host Interactions

Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice

[Immunoprotective Effects of Helicobacter Pylori UreB and HpaA Bivalence Recombinant Vaccine with Inner Adjuvant on Experimental Infection in Mice].

The Experimental Study of Plasmid DNA Encoding S.mutans Surface Protein Pac Immunized Mice

[Immunoprotective Effect of Combined Pneumococcal Endopeptidase O and Pneumococcal Surface Adhesin A Vaccines Against Streptococcus Pneumoniae Infection].

Mucosal Immunization with Purified ClpP Could Elicit Protective Efficacy Against Pneumococcal Pneumonia and Sepsis in Mice

Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

Association of natural induced antibodies against select Group B streptococcus surface proteins and invasive disease in early infancy